| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Mount Sinai School of Medicine, New York, NY.
Address correspondence and reprint requests to Dr. Stanley Tuhrim, Department of Neurology, Box 1137, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029.
OBJECTIVE: To determine whether elevated titers of antiphosphatidyl serine antibodies (aPS) are associated with an increased risk of ischemic stroke in a general stroke population.
BACKGROUND: aPS are members of the family of antiphospholipid antibodies that has been associated with increased stroke risk. Although aPS have been demonstrated to occur in 18% of a group of young patients with cerebrovascular symptoms, their prevalence in the general stroke population is unknown, and no controlled study to assess the strength of their association with ischemic stroke has been undertaken previously.
METHODS: A case-control study comparing 267 acute ischemic stroke patients and 653 community controls. Sera were obtained immediately after acute stroke in patients. Titers of IgG aPS >16 IgG phospholipid units or IgM aPS >22 IgM phospholipid units were considered positive. Odds ratios (ORs) were obtained by logistic regression, adjusting for age, gender, race/ethnicity, history of hypertension, diabetes mellitus, cardiovascular disease, and cigarette smoking.
RESULTS: The adjusted OR was 5.6 (95% confidence interval [CI] 1.8, 18.0) for IgG aPS and 2.9 (95% CI 1.6, 5.3) for IgM aPS. The adjusted OR for either an elevated IgG or IgM aPS was 3.2 (95% CI 1.8, 5.5).
CONCLUSIONS: This study demonstrates that elevated IgG and IgM antiphosphatidyl serine antibodies titers are associated with increased risk of ischemic stroke. The prevalence of these antibodies is lower, but the associated stroke risk is comparable with that of anticardiolipin antibodies.
Key words: Antiphosphatidyl serine—Antiphospholipid—Stroke risk—Infarction—Anticardiolipin—Antibody.
This article has been cited by other articles:
|
|
 |
|
  T. Kahles, M. Humpich, H. Steinmetz, M. Sitzer, and E. Lindhoff-Last Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke Rheumatology, September 1, 2005; 44(9): 1161 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 APASS Investigators Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke JAMA, February 4, 2004; 291(5): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tanne, S.R. Levine, R.L. Brey, H. Lin, and B.C. Tilley Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial Neurology, October 28, 2003; 61(8): 1158 - 1159. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Dambinova, G. A. Khounteev, G. A. Izykenova, I. G. Zavolokov, A. Y. Ilyukhina, and A. A. Skoromets Blood Test Detecting Autoantibodies to N-Methyl-D-aspartate Neuroreceptors for Evaluation of Patients with Transient Ischemic Attack and Stroke Clin. Chem., October 1, 2003; 49(10): 1752 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R L Brey, J Chapman, S R Levine, G Ruiz-Irastorza, R H. Derksen, M Khamashta, and Y Shoenfeld Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 Lupus, July 1, 2003; 12(7): 508 - 513. [Abstract] [PDF]
|
|
|
|
|
|
G. Sanna, M. L. Bertolaccini, M. J. Cuadrado, M. A. Khamashta, and G. R. V. Hughes Central nervous system involvement in the antiphospholipid (Hughes) syndrome Rheumatology, February 1, 2003; 42(2): 200 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Luong, J. H. Rand, X.-X. Wu, J. H. Godbold, M. Gascon-Lema, and S. Tuhrim Seasonal Distribution of Antiphospholipid Antibodies Stroke, August 1, 2001; 32(8): 1707 - 1711. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
